Review



mog35 55 peptide  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress mog35 55 peptide
    Mog35 55 Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 16 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm41857575-76-9-12?v=MedChemExpress
    Average 95 stars, based on 16 article reviews
    mog35 55 peptide - by Bioz Stars, 2026-08
    95/100 stars

    Images



    Similar Products

    myelin oligodendrocyte glycoprotein peptide mog35 55  (Genemed Synthesis)
    86
    Genemed Synthesis myelin oligodendrocyte glycoprotein peptide mog35 55
    Myelin Oligodendrocyte Glycoprotein Peptide Mog35 55, supplied by Genemed Synthesis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm42285103-323-21-26?v=Genemed+Synthesis
    Average 86 stars, based on 1 article reviews
    myelin oligodendrocyte glycoprotein peptide mog35 55 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    mog35 55 peptide  (MedChemExpress)
    95
    MedChemExpress mog35 55 peptide
    Mog35 55 Peptide, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm41857575-76-9-12?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    mog35 55 peptide - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    mog35 55  (MedChemExpress)
    95
    MedChemExpress mog35 55
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Mog35 55, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pmc13123086-53-6-29?v=MedChemExpress
    Average 95 stars, based on 1 article reviews
    mog35 55 - by Bioz Stars, 2026-08
    95/100 stars
    		  Buy from Supplier
    mog35 55 peptide  (Synpeptide Co Ltd)
    86
    Synpeptide Co Ltd mog35 55 peptide
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Mog35 55 Peptide, supplied by Synpeptide Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm41547456-77-34-38?v=Synpeptide+Co+Ltd
    Average 86 stars, based on 1 article reviews
    mog35 55 peptide - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    mog35  (Biosynth Carbosynth)
    92
    Biosynth Carbosynth mog35
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Mog35, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/bio_rxiv__64898__2026__01__08__698420-262-28-30?v=Biosynth+Carbosynth
    Average 92 stars, based on 1 article reviews
    mog35 - by Bioz Stars, 2026-08
    92/100 stars
    		  Buy from Supplier
    mog35 55 specific 2d2 tcrtransgenic mice  (Jackson Laboratory)
    86
    Jackson Laboratory mog35 55 specific 2d2 tcrtransgenic mice
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Mog35 55 Specific 2d2 Tcrtransgenic Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm41371223-244-3-9?v=Jackson+Laboratory
    Average 86 stars, based on 1 article reviews
    mog35 55 specific 2d2 tcrtransgenic mice - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier
    mog35 55 peptide powder  (MedChemExpress)
    94
    MedChemExpress mog35 55 peptide powder
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Mog35 55 Peptide Powder, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pm41265623-52-17-44?v=MedChemExpress
    Average 94 stars, based on 1 article reviews
    mog35 55 peptide powder - by Bioz Stars, 2026-08
    94/100 stars
    		  Buy from Supplier
    myelin oligodendrocyte glycoprotein mog peptide mog35 55  (Genemed Synthesis)
    86
    Genemed Synthesis myelin oligodendrocyte glycoprotein mog peptide mog35 55
    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of <t>MOG35-55-induced</t> EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control
    Myelin Oligodendrocyte Glycoprotein Mog Peptide Mog35 55, supplied by Genemed Synthesis, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mog35+55/pmc11614491-796-0-7?v=Genemed+Synthesis
    Average 86 stars, based on 1 article reviews
    myelin oligodendrocyte glycoprotein mog peptide mog35 55 - by Bioz Stars, 2026-08
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of MOG35-55-induced EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control

    Journal: Journal of Neuroinflammation

    Article Title: TRIM21 promotes astrocyte-mediated neuroinflammation in experimental autoimmune encephalomyelitis by stabilizing RGMa via K33-linked ubiquitination

    doi: 10.1186/s12974-026-03769-4

    Figure Lengend Snippet: RGMa is upregulated in MS patients and EAE mice and localizes to astrocytes. A RGMa levels in peripheral blood samples from MS patients (n = 117) and controls (n = 50), as quantified by ELISA. B Schematic depicting the time course of MOG35-55-induced EAE in the murine model. C Clinical scores of EAE mice following immunization with MOG35-55 peptide (n = 12). D Representative Western blot analysis of RGMa protein expression in brain lysates from EAE mice at 28 dpi (n = 5). E Corresponding Western blot analysis of RGMa expression in spinal cord lysates from EAE mice at 28 dpi (n = 5). F Quantitative assessment of RGMa protein expression in brain lysates, normalized to GAPDH (n = 5). G Quantification of RGMa expression in spinal cord lysates, normalized to GAPDH (n = 5). H Immunofluorescence analysis illustrating the spatial distribution and co-localization of RGMa (red) with the astrocyte marker glial fibrillary acidic protein (GFAP, green) in brain and lumbar spinal cord sections between control and EAE mice at 28 dpi (n = 5). Note: IgG isotype controls confirmed staining specificity (Fig. S2). Scale bar, 50 µm. DAPI, 4',6-Diamidino-2'-phenylindole. I Inflammatory cytokine mRNA expression levels of IL-1β, IL-6, and CCL2 in primary astrocytes at 24 hours after lentivirus-mediated overexpression of RGMa or vector control

    Article Snippet: After 10 days of induction with MOG35-55 by which time mice gradually exhibited tail weakness, the mice were randomly assigned to receive daily intraperitoneal injections of either Quisinostat (HY-12726, MedChemExpress, USA) at 10 mg/kg or an equal volume of vehicle control for 2 weeks.

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Expressing, Immunofluorescence, Marker, Control, Staining, Over Expression, Plasmid Preparation